La Jolla-based biopharmaceuticals developer Ambrx has set its initial estimated pricing range for its IPO, saying in a filing this morning that it expects to price its IPO at between $12.00 and $14.00 per share. The offering will raise around $86.94M for the company. Ambrx has applied to list on the NASDAQ Global Market as AMBX. The company is venture backed by Tavistock, Maverick Capital, Apposite Healthcare, Versant Ventures, 5AM VEntures, Roche, and Merck, among others. Ambrx is developing optimized protein therapeutics known as bio-conjugates.